# Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

> **NCT04707573** · PHASE2 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 22 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Vadadustat

## Key facts

- **NCT ID:** NCT04707573
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-08
- **Primary completion:** 2010-09-24
- **Final completion:** 2010-09-24
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04707573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04707573, "Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04707573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*